Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2018

To view an abstract, select an author from the vertical list on the left.

2018 Grants - Petersen

Alzheimer's Disease Biomarker Combinations in the Community

Ronald C. Petersen, M.D.
Mayo Clinic
Rochester, Minnesota

2018 Zenith Fellows Award (ZEN)

How do toxic forms of tau and beta-amyloid interact to promote Alzheimer's disease?

Two key biomarkers (or biological factors) of Alzheimer's disease are the protein fragment beta-amyloid and the protein tau. These molecules become abnormal in the Alzheimer's brain and form harmful clumps called amyloid plaques and neurofibrillary tangles. Until recently, clinicians could only measure tau and beta-amyloid levels in a person with dementia once that person had died. We now, however, have two methods of measuring these pathologies in living individuals: imaging the brain with positron emission tomography (PET) scans and testing protein levels in cerebrospinal fluid (the fluid that surrounds the brain). Scientists are beginning to use these tools to reveal how tau and beta-amyloid may interact to increase Alzheimer's disease risk.

Research Plan
For their research grant, Ronald C. Petersen, M.D., and colleagues will use PET imaging and CSF testing to examine how brain health is affected by both tau and beta-amyloid clumping. The researchers will assess protein levels in about 3,000 older individuals from the Mayo Clinic Study of Aging. Most participants will begin the study with cognitively normal (healthy) brains or with mild cognitive impairment (MCI), a condition of subtle memory loss that often precedes Alzheimer's. These individuals will then be examined over time to determine how tau and beta-amyloid clumping — either alone or in combination — might influence whether the cognitively normal people develop MCI, or whether the people with MCI develop Alzheimer's disease.

Results of this study could shed new light on how cognitive decline occurs at the molecular level. The study could also provide important data for future clinical trials that seek to identify novel therapies for targeting tau, beta-amlyoid, or both.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.